Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00728091 · ClinicalTrials.gov registry record · Phase 3
A Phase III Study Evaluating the Efficacy and Safety of Satavaptan Versus Placebo in Patients With Dilutional Hyponatremia
A Phase 3 study, sponsored by Sanofi.
- Terminated
- Registry status
- Phase 3
- Development phase
- 2
- Enrollment target
NCT00728091 is a Phase 3 study that was terminated before completion, run by Sanofi. The registered enrollment target is 2 participants.
The verdict
NCT00728091, a Phase 3 study, was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 2 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the efficacy of satavaptan versus placebo in participants with dilutional hyponatremia due to SIADH. Secondary objectives are to assess the safety of satavaptan, the maintenance of effect, and the clinical benefit in these participants.
Interventions
- DRUG placebo
- DRUG Satavaptan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2008-07 |
| Est. Completion | 2008-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00728091
The ClinicalTrials.gov registry entry for NCT00728091 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00728091 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00728091 about?
NCT00728091 is a clinical study titled "A Phase III Study Evaluating the Efficacy and Safety of Satavaptan Versus Placebo in Patients With Dilutional Hyponatremia". The primary objective of this study is to assess the efficacy of satavaptan versus placebo in participants with dilutional hyponatremia due to SIADH. Secondary objectives are to assess the safety of satavaptan, the maintenance of effect, and the clinical benefit in these participants.
What is the current status of trial NCT00728091?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 2 participants. The study started on 2008-07. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00728091?
The interventions under investigation include: placebo (DRUG), Satavaptan (DRUG).
Who is sponsoring clinical trial NCT00728091?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.